Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy

Poonawalla, Insiya B.; Piller, Linda B.; Lairson, David R.; Chan, Wenyaw; Du, Xianglin L.

doi:10.1097/igc.0000000000000564

Cited by 9 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis from the Surveillance, Epidemiology, End Results database showed that erythropoietin-stimulating agents and granulocyte colony-stimulating factors were effective and improved OS in elderly EOC patients. 31 In the present series, approximately 20% of the patients received supportive care during chemotherapy.…”

Section: Discussionmentioning

confidence: 73%

Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index

Ferrero¹,

Fuso²,

Tripodi³

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 73%

Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index

Ferrero¹,

Fuso²,

Tripodi³

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Both CSFs and ESAs are commonly used to prevent infection and neutropenia in patients receiving chemotherapy and for the treatment of asthenia by stimulating the growth of red blood cells, respectively (115-117). The use of CSFs and ESAs results in better cancer patient adherence to chemotherapy without a reduction in dose administration, thus improving the clinical outcomes of the therapy (118,119).…”

Section: Pathophysiologymentioning

confidence: 99%

Cancer-associated stroke: Pathophysiology, detection and management (Review)

et al. 2019

View full text Add to dashboard Cite

Numerous types of cancer have been shown to be associated with either ischemic or hemorrhagic stroke. In this review, the epidemiology and pathophysiology of stroke in cancer patients is discussed, while providing vital information on the diagnosis and management of patients with cancer and stroke. Cancer may mediate stroke pathophysiology either directly or via coagulation disorders that establish a state of hypercoagulation, as well as via infections. Cancer treatment options, such as chemotherapy, radiotherapy and surgery have all been shown to aggravate the risk of stroke as well. The clinical manifestation varies greatly depending upon the underlying cause; however, in general, cancer-associated strokes tend to appear as multifocal in neuroimaging. Furthermore, several serum markers have been identified, such as high D-Dimer levels and fibrin degradation products. Managing cancer patients with stroke is a delicate matter. The cancer should not be considered a contraindication in applying thrombolysis and recombinant tissue plasminogen activator (rTPA) administration, since the risk of hemorrhage in cancer patients has not been reported to be higher than that in the general population. Anticoagulation, on the contrary, should be carefully examined. Clinicians should weigh the benefits and risks of anticoagulation treatment for each patient individually; the new oral anticoagulants appear promising; however, low-molecular-weight heparin remains the first choice. On the whole, stroke is a serious and not a rare complication of malignancy. Clinicians should be adequately trained to handle these patients efficiently.

show abstract

“…Supporting this model, the present results showed that type II EOC was more common in elderly women than in younger patients. The extremely poor prognosis of elderly EOC may be due to different tumor biological characteristics, discrepancies in clinical practice, and skewed distribution of clinicopathological characteristics [39,[47][48][49][50][51]. Advanced age was associated with prognosis after the influences of FIGO stage, histological type, and even the surgical outcome were excluded in the type II EOC patients who received optimal debulking, although the independence has been demonstrated by previous studies [15,24].…”

Section: Discussionmentioning

confidence: 95%

Prognostic factors for types I and II epithelial ovarian cancer in the elderly

Cheng¹,

Zhou²,

Yang³

et al. 2020

EJGO

View full text Add to dashboard Cite

No consensus exists on whether age is independently associated with poor prognosis in epithelial ovarian cancer (EOC). This study aimed to examine the prognostic factors of EOC in elderly patients. Materials and Methods: A total of 665 EOC patients from Jiangsu Institute of Cancer Research (JICR, People's Republic of China) were retrospectively analyzed between 1996 and 2015. For validation, 990 cases who consulted at MD Anderson Cancer Center (MDACC, USA) from 1990 to 2011 were recruited. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test. Results: Histological type II (p = 0.01) and suboptimal surgery outcome (p = 0.00) were more common in the elderly (age ≥ 70 years) patients with EOC than in younger patients from JICR. The International Federation of Gynecology and Obstetrics (FIGO) stage, histological type, and optimal surgery were independently associated with overall survival (OS; p = 0.00, p = 0.03, and p = 0.00, respectively) and progression-free survival (PFS; p = 0.00, p = 0.02, and p = 0.00, respectively) in the EOC patients. Both OS and PFS were lower in the elderly patients with type I EOC than in the younger cases (136.5 months vs. 191.8 months at p = 0.00 and 35.5 months vs. 75.1 months at p = 0.01, respectively). The OS and PFS of the elderly patients were poorer than those of the younger cases with type II EOC (38.4 months vs. 42.3 months at p = 0.00 and 14.9 months vs. 16.8 months, p = 0.04, respectively). In type II ovarian cancer patients who achieved optimal debulking, the median OS and PFS durations of younger patients remained longer than those of elderly patients (50.2 months vs. 68.0 months, p = 0.00 and 14.9 months vs. 19.2 months, p = 0.01, respectively). Conclusions: Compared with young patients, elderly EOC more commonly presented with an aggressive histological type and poor performance status and was more frequently undertreated. Advanced age was independently associated with poor prognosis in EOC, even after the influence of histological type and surgical outcome was eliminated.

show abstract

Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy

Cited by 9 publications

References 28 publications

Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index

Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index

Cancer-associated stroke: Pathophysiology, detection and management (Review)

Prognostic factors for types I and II epithelial ovarian cancer in the elderly

Contact Info

Product

Resources

About